David Chu, MD
Ophthalmology · New York, NYNPI 1144260019
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,746 of the $234,333 with a category attached, or 78.0%. Mallinckrodt Hospital Products Inc. accounts for 61.2% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $106,453, 4.1 times the $25,710 reported in 2019. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 638 payments — averaging $367.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$144K
- Bausch & Lomb Americas Inc.$47K
- Mallinckrodt Enterprises LLC$15K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$7K
- Dompe US, Inc.$5K
- AbbVie$5K
- plus $12K from 24 others
Across 35 payments — averaging $28,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$767K
- Mallinckrodt Enterprises LLC$131K
- Gilead$64K
- Glaukos Corporation$14K
- Eyepoint US, Inc.$5K
What the payments were for
- Consulting fees$25,17511%
- Speaking & faculty fees$182,74678%
- Travel & lodging$10,5995%
- Food & beverage$15,7137%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 123 | $143,526 |
| Bausch & Lomb Americas Inc. | 91 | $47,261 |
| Mallinckrodt Enterprises LLC | 17 | $14,824 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $6,529 |
| Dompe US, Inc. | 15 | $5,440 |
| AbbVie(2 entities) | 52 | $4,555 |
| Harrow Eye, LLC | 22 | $3,883 |
| Sun Pharmaceutical Industries Inc. | 99 | $1,502 |
| Sight Sciences, Inc. | 15 | $814 |
| ANI Pharmaceuticals, Inc. | 28 | $641 |
| Eyepoint US, Inc. | 7 | $626 |
| Oyster Point Pharma, Inc. | 26 | $551 |
| Tarsus Pharmaceuticals, Inc. | 15 | $507 |
| Rxsight Inc | 7 | $456 |
| Alcon | 17 | $390 |
| Novartis | 32 | $382 |
| Amgen(2 entities) | 13 | $339 |
| Ocular Therapeutix, Inc. | 15 | $338 |
| Aerie Pharmaceuticals, Inc. | 6 | $289 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $277 |
| Glaukos Corporation | 2 | $243 |
| Kala Pharmaceuticals, Inc. | 15 | $209 |
| Rayner Intraocular Lenses Limited | 1 | $164 |
| Alimera Sciences, Inc. | 2 | $149 |
| Samsara Vision | 1 | $139 |
| NEW World Medical,inc. | 1 | $133 |
| Eyevance Pharmaceuticals LLC | 5 | $85 |
| Biotissue Holdings Inc. | 2 | $43 |
| Beaver-visitec International, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$156,115
- XIPERE$45,580
- LOTEMAX$13,000
- RETISERT$6,500
- Oxervate$5,157
- TRIESENCE$3,500
- Humira$3,115
- VEVYE$2,800
- OMNI(R) SURGICAL SYSTEM (US)$652
- RXSIGHT CONTACT LENS$413
- RXSIGHT INJECTOR CARTRIDGE$413
- RXSIGHT INJECTOR HANDPIECE$413
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$413
- DURYSTA$375
- YUTIQ$363
- Rhopressa$359
- Rocklatan$359
- CEQUA$274
- XDEMVY$267
- LIGHT ADJUSTABLE LENS (LAL)$267
How this compares
$234,333 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 28 | $774,821 |
| Humira(Cf)Adalimumab | 28 | $273,919 |
| Humira(Cf) PenAdalimumab | 29 | $220,681 |
| RestasisCyclosporine | 68 | $76,428 |
| Prednisolone Acetate | 922 | $45,355 |
| XiidraLifitegrast | 36 | $38,315 |
| ZirganGanciclovir | 51 | $23,080 |
| ValacyclovirValacyclovir Hcl | 310 | $20,200 |
| LumiganBimatoprost | 50 | $19,458 |
| Cyclosporine | 47 | $18,370 |
| Mycophenolate Mofetil | 132 | $16,617 |
| CombiganBrimonidine Tartrate/Timolol | 55 | $16,225 |
| TyrvayaVarenicline Tartrate | 25 | $16,055 |
| EvoxacCevimeline Hcl | 14 | $12,825 |
| Bromfenac Sodium | 93 | $12,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $5,440 | $774,82128 claims |
| AbbVieHumira(Cf), Restasis, Lumigan, Combigan, Alphagan P | $4,555 | $395,289236 claims |
| Bausch & Lomb Americas Inc.Xiidra, Zirgan, Vyzulta | $47,261 | $65,904101 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax | $6,529 | $21,37795 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $551 | $16,05525 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $289 | $12,63131 claims |
| NovartisDurezol | $382 | $9,68616 claims |
| AlconSimbrinza | $390 | $9,17942 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $85 | $2,94813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- Joshua KimNew York$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.